mTOR controls kidney epithelia in health and disease
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Renal epithelial function is the cornerstone of key excretory processes performed by our kidneys. Most of these tasks need to be tightly controlled to keep our internal environment in balance. Recently, the mTOR signalling network emerged as a key pathway controlling renal epithelial cells from the glomerular tuft along the entire nephron. Both mTOR complexes, mTORC1 and mTORC2, regulate such diverse processes as glomerular filtration and the fine tuning of tubular electrolyte balance. Most importantly, dysregulation of mTOR signalling contributes to prevalent kidney diseases like diabetic nephropathy and cystic kidney disease. The following review shall summarize our current knowledge of the renal epithelial mTOR signalling system under physiological and pathophysiological conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
mTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676 · cited 1×
“For a comprehensive and detailed general overview of mTOR signalling cascades we refer to several recent reviews and review series [19–22].”
BackgroundSabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
The role of the Atg1/ULK1 complex in autophagy regulation
Mizushima, N. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.12.004 · Cited by 1,062
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907 · cited 1×
“In these it could be demonstrated that mTORC2 is critical to phosphorylate the hydrophobic motif of SGK1 at Thr 422 which in turn is a prerequisite for PDK1 to phosphorylate and activate the kinase domain of SGK1 at Thr 256 [16, 74].”
BackgroundAmino acid signalling upstream of mTOR
Jewell, J. L., Russell, R. C., & Guan, K.-L. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3522 · Cited by 894 · cited 1×
“For a comprehensive and detailed general overview of mTOR signalling cascades we refer to several recent reviews and review series [19–22].”
BackgroundHartleben, B., Gödel, M., Meyer-Schwesinger, C., Liu, S., Ulrich, T., Köbler, S., Wiech, T., Grahammer, F., Arnold, S. J., Lindenmeyer, M. T., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39492 · Cited by 721 · cited 1×
“In fact, inhibition of autophagy itself causes a degenerative glomerulopathy [58].”
BackgroundSelf-citationRole of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547 · cited 8×
“Podocyte-specific disruption of the mTORC1 complex resulted in a pathological picture, which clinically most closely resembles secondary focal and segmental glomerulosclerosis (FSGS) with quite stable proteinuria and slow progression [29].”
BackgroundInfluentialSelf-citationmTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538 · cited 4×
“However, podocyte dysfunction was directly associated with mTORC1-induced endoplasmic reticulum (ER) stress and the reduction of ER stress by using the chemical chaperon (4-phenylbutyrate) abolished podocyte loss in podocyte-specific TSC1 knock-out (KO) mice [28].”
BackgroundResultInfluentialSelf-citationRapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531 · cited 1×
“For a comprehensive and detailed general overview of mTOR signalling cascades we refer to several recent reviews and review series [19–22].”
BackgroundRAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481 · cited 1×
“This notion is supported by mutations in yeast TOR1, TOR2 or FKBP 12 which lead to resistance to the growth-inhibitory properties of rapamycin [10–12].”
MethodDazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460 · cited 1×
“For a comprehensive and detailed general overview of mTOR signalling cascades we refer to several recent reviews and review series [19–22].”
BackgroundActivating AMP-activated protein kinase (AMPK) slows renal cystogenesis
Takiar, V., Nishio, S., Seo-Mayer, P., King, J. D., Li, H., Zhang, L., Karihaloo, A., Hallows, K. R., Somlo, S., & Caplan, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011498108 · Cited by 345
Inhibition of MTOR Disrupts Autophagic Flux in Podocytes
Cinà, D. P., Onay, T., Paltoo, A., Li, C., Maezawa, Y., De Arteaga, J., Jurisicova, A., & Quaggin, S. E. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070690 · Cited by 172 · cited 1×
“However, although a podocyte-specific complete mTOR KO results in impaired autophagic flux [59], the phenotypes of constitutively mTOR hyper-activated podocytes and autophagy depleted podocytes have only very little overlap suggesting that autophagy is not the major downstream pathway of mTOR in mediating podocyte inj…”
BackgroundThe physiological impact of the serum and glucocorticoid-inducible kinase SGK1
Lang, F., Artunc, F., & Vallon, V. (2009) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e32832f125e · Cited by 139 · cited 1×
“SGK1 is known to be intimately involved in the regulation of aldosterone sensitive distal tubular sodium reabsorption [75].”
Background
Cited by
The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging
Kennedy, B. K., & Lamming, D. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.009 · Cited by 544
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Self-citationTargeting mTOR Signaling Can Prevent the Progression of FSGS
Zschiedrich, S., Bork, T., Liang, W., Wanner, N., Eulenbruch, K., Munder, S., Hartleben, B., Kretz, O., Gerber, S., Simons, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016050519 · Cited by 76
Self-citationTherapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“Whereas, the precise roles played by mTORC1 and mTORC2 complexes in the different types of renal cells is not fully unveiled during development nor in the adulthood, it is suggested that mTOR signaling pathways impact glomerular and tubulointerstitial renal physiological processes [54].”
Background
Metadata
- Authors
- Grahammer, F., Wanner, N., & Huber, T. B.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-01
- Volume
- 29
- Issue
- suppl 1
- Pages
- i9-i18
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2135900832
- Cited by
- 61
- References
- 17
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.